Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome

Trial Profile

Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Metabolic syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Nov 2016 New trial record
    • 01 Nov 2016 Results assessing effect of Valsartan on retinal capillary rarefaction in hypertensive patients (n=150) using patients data from this and other two trials (NCT01318395 and NCT00152698) published in the Journal of Clinical Hypertension (Greenwich)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top